GSK reports breakthrough results in chronic hepatitis B trials

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial

Addex spin-out Neurosterix launches Phase 1 trial for novel schizophrenia drug

NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 receptor

Newron secures key European patent for schizophrenia drug Evenamide

This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation

Alumis reports breakthrough Phase 3 results for oral psoriasis therapy

The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data

Stereotaxis scores FDA nod for groundbreaking MAGiC robotic heart catheter

The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures

Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy

REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS

ICMR & Panacea Biotec complete enrollment for India's first indigenous dengue vaccine phase 3 study

DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027